CNS Pharmaceuticals
NASDAQ: CNSPHouston, US · Nevada corporation
Find your way into CNS Pharmaceuticals
362 people in our graph share verified history with the CNS Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Arnon Dinurunlockedknows Rami Levin · together at Tel Aviv University (overlapped)
×4knows the team · via Tel Aviv University
×2knows the team · via HKUST Business School
×5knows the team · via Thunderbird School of Global Management
CNS Pharmaceuticals is a biotechnology company developing therapies for neurological and oncological diseases with significant unmet medical needs. The company focuses on identifying and advancing differentiated therapeutic candidates to improve patient outcomes.
Founders & leadership
RL
Rami LevininPresident & Chief Executive OfficerHe has over 30 years of experience in life sciences leadership across early-stage companies and public firms, with background in drug development, commercialization of oncology and specialty therapies, M&A, and capital formation, including prior CEO roles at Saniona and ImStem Biotechnology and leadership positions at Sobi North America and Merck KGaA/Serono.
SO
Steve O'LoughlininChief Financial Officer
LK
Lynne KelleyChief Medical Officer
EF
Eric FaulknerChief Technology Officer
DW
Dylan WenkeChief Business Officer
Board
AM
Amy MaheryBoard director
JK
Jeffry KeyesBoard director
FC
Faith CharlesBoard director
MF
Michal FisherBoard director
BC
Bettina CockroftBoard director
Reported raises · per SEC filings
Form D private placements$22.5M disclosed across 1 round · 2026
▶$22.5MraisedMay 2026 · 13 investors · PharmaceuticalsRule 506(b)
▶$22.5MraisedMay 2026 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rami LevinExecutive Officer, Director
- Amy MaheryDirector
- Jeffry KeyesDirector
- Steve O'LoughlinExecutive Officer
- Faith CharlesDirector
- Michal FisherDirector
- Bettina CockroftDirector
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- Sales commissions
- $1.6M
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- May 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Cenexelresearch25 shared keywordsCenExel operates a network of clinical research centers that conduct trials and studies to advance new medical treatments. The company serves pharmaceutical sponsors, biotech firms, and patients by providing clinical research infrastructure and expertise across 18 sites in the United States.
Companies competing with CNS Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Strategic Transformation at Virtual Investor Conferencenetworknewswire.wordpress.com · Aug 2026
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference - BioSpacebiospace.com · Aug 2026
CNS Pharmaceuticals (CNSP) raises $22.5M, extends cash runway despite higher lossstocktitan.net · Aug 2026
CNS Pharmaceuticals outlines pivot, $22.5M raise | CNSP 8-K Filingstocktitan.net · Jul 2026
CNS Pharmaceuticals (CNSP) registers 9.79M shares including prefunded warrantsstocktitan.net · May 2026
The Truth Behind CNS Pharmaceuticals Recent Stock Surgeharianbasis.co · May 2026Frequently asked questions
- What does CNS Pharmaceuticals do?
- CNS Pharmaceuticals is a biotechnology company developing therapies for neurological and oncological diseases with significant unmet medical needs. The company focuses on identifying and advancing differentiated therapeutic candidates to improve patient outcomes.
- How much funding has CNS Pharmaceuticals raised?
- CNS Pharmaceuticals has disclosed $22.5M raised across 1 round.
- Where is CNS Pharmaceuticals headquartered?
- CNS Pharmaceuticals is headquartered in Houston, US.